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Objectives: To investigate the differences between bone mineral density (BMD), lean and fat mass of human immunodeficiency
virus (HIV-) positive and HIV-negative black women and to investigate factors associated with low BMD.
Methods: Case-control study of black women (n = 565) aged 29–65 years from Potchefstroom, North West province, South
Africa, based on secondary analysis of data. Total BMD, left femur neck of the hip (LFN BMD), spine BMD, total fat, fat-free
tissue mass and percentage body fat (%BF) were measured by dual-energy X-ray absorptiometry.
Results: HIV-negative women had significantly higher median BMD, %BF, appendicular skeletal mass (ASM), ASM index, body
mass index (BMI) and waist circumference than HIV-positive women. When the groups were matched for age and BMI, only
spine BMD was marginally lower in HIV-positive women. In the total group, age, smoking and HIV status were associated
with lower BMD, while calcium intake was positively associated with BMD. Similar variables were associated with BMD in
HIV-negative women, while age and educational status were associated with BMD in HIV-positive women.
Conclusion: Low BMD was more common among HIV-positive than HIV-negative women. Older HIV-positive women with low
educational status are particularly at risk.
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Introduction
South Africa is experiencing rapid urbanisation.1 Despite having
multiple beneficial effects, urbanisation is associated with health
consequences due to the accompanying lifestyle changes,
including changes in compromised bone health.1,2 Emerging
evidence indicates that black, urban postmenopausal women
are at increased risk of the development of low bone mass,
decreased bone formation and bone turnover, as well as
increased bone degradation resulting from inadequate dietary
intake, reduced physical activity and low vitamin D status.1,3
Conflicting results regarding the individual associations
between lean mass, as well as fat mass, with bone mineral
density (BMD) have been previously demonstrated.4 A cross-sec-
tional study conducted by Sotunde and co-workers (2015) has
shown that lean mass has a stronger association with BMD in
comparison with fat mass in urban black South African women.5
It was previously believed that black women had a greater pro-
tection against the development of osteoporosis in comparison
with white women due to their enhanced BMD. Studies indicat-
ing this difference were primarily conducted in America and
Europe.6,7 However, over the last few decades osteoporosis
has been recognised as a disease with a high incidence in urba-
nised areas in low- and middle-income countries, including
South Africa.3 The effects of human immunodeficiency virus
(HIV) infection on bone metabolism has not been recognised
as a cause of substantial increase in the prevalence of osteope-
nia and osteoporosis amongst HIV-infected patients in compari-
son with non-HIV-infected patients.8–11 Amorosa and Tebas
(2006) concluded that this might be due to the small sample
sizes of earlier studies, thus limiting the strength of their
conclusions.12
HIV infection is considered to be a chronic but treatable
disease.13 The life expectancy of people living with this virus
has increased due to the introduction of antiretroviral therapy
(ART).14 Even though the incidence of acquired immune
deficiency syndrome (AIDS) associated co-morbidities has
decreased, other conditions such as osteoporosis and fragility
fractures have increased.15–18 A variety of factors could be
responsible for the bone loss and fracture risk, including HIV-
associated inflammation, lifestyle and behavioural factors, co-
morbid conditions and ART itself, as well as an underlying
genetic predisposition.19–23
Studies in Europe, the United States of America and South
America regarding the initiation of ART have shown a 2–6%
reduction in hip and spine BMD within the first 24–48 weeks
after initiation of ART.24–27 The rates of osteoporosis and osteo-
penia were found to increase by 15% and 67% respectively, with
a 3.7 fold higher osteoporosis rate and 6.4 fold higher decrease
in BMD in HIV-positive individuals.28 An increased fracture risk
was found in HIV-positive individuals compared with HIV-nega-
tive individuals.18 The issue of bone health and HIV remains neg-
lected in terms of research and management in Africa, despite
the fact that sub-Saharan Africa has a higher incidence of HIV
infection than any other region.29 Evidence suggests lack of suf-
ficient data on HIV/AIDS and metabolic bone diseases in a
region housing two-thirds of persons living with the virus
worldwide.30
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The aim of this study was therefore to investigate the differences
between BMD, lean and fat mass of HIV-positive and HIV-nega-
tive black women, and to investigate factors associated with low
BMD among HIV-positive and HIV-negative women.
Methods
Setting and design
This study was based on secondary analysis of data collected
from 2012 to 2014 in two different studies, conducted in Potch-
efstroom, as indicated in Figure 1. The first study during 2012–
2013 (n = 183) was a cohort study to assess associations
between environmental variables (such as diet and physical
activity) and BMD, while the aim of the second study (n = 382)
was to assess the association between body mass index (BMI)
and percentage body fat categories.
Inclusion criteria for the first study were: female participants of
black ethnicity, 35–65 years of age, apparently healthy and
able to understand English, Afrikaans or Setswana. Participants
who were stable and on chronic medication for diseases such
as hypertension and HIV infection were included. Exclusion cri-
teria were: men, pregnant or lactating women and women
younger than 35 years or older than 65 years of age. Participants
with any other diagnosed acute or non-communicable chronic
diseases were also excluded from the study.
The following data were collected on 183 women: sociodemo-
graphic data, anthropometry, physical activity, whole-body
BMD, left femur neck of the hip (LFN) BMD and spine BMD, fat
tissue mass and fat-free tissue mass of the whole bodymeasured
by dual-energy X-ray absorptiometry (DXA). In addition, dietary
intakes of the same participants were measured by validated
quantitative food frequency questionnaire (QFFQ)31 and phys-
ical activity was measured using a modified Baecke physical
activity questionnaire validated for this population.32
During 2014, women (n = 382) were recruited for the second
study, but in this study, only whole-body BMD, anthropometry
and sociodemographic data were collected, while physical activity
and dietary data were not collected due to lack of resources.
Inclusion criteria for the second study were: apparently healthy,
black individuals between the ages of 32 and 93 years, who lived
in the study areas for most days of the week. Participants who
were stable and on chronic medication for diseases such as
hypertension, type 2 diabetes mellitus and HIV infection were
included.
Exclusion criteria: black adults younger than 32 and older than
95 years, who did not live in the study areas on most days of
the week. Participants that did not give informed consent, or
who were pregnant and acutely ill, were also excluded.
Figure 1: Study methods and number of study participants for this study.
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A total of 565 apparently healthy, urban women were available
for this study, of whom 103 were HIV-positive. Because 23
women declined HIV testing, complete data for 542 participants
were available for analysis. Within the total group, data for spine
and LFN BMDwere only available for 25 HIV-positive women and
145 HIV-negative women, while physical activity data were only
available for 33 HIV-positive women and 150 HIV-negative
women, respectively (Figure 1).
The current study was a case-control study of these urban, black
women aged 29–65 years, from Potchefstroom in the North
West province, South Africa and secondary analysis of the data
collected as described above. Inclusion criteria were female
gender, black ethnicity, 29–65 years old and not physically dis-
abled. Women previously diagnosed with hypertension were
included, because exclusion of these women would result in a
smaller, non-representative sample, since almost one-third of
the adult South African population has hypertension.33 Exclusion
criteria were pregnancy, lactation and participants with any
other diagnosed acute or chronic disease, excluding hyperten-
sion and known HIV infection. In addition, each participant
was tested for HIV infection on the study day in order to
confirm HIV status.
Ethics approval was obtained for secondary data analysis from
the Health Research Ethics Committee (NWU-00061-17-S1),
North-West University (NWU), Potchefstroom Campus. The orig-
inal projects were conducted under ethical conditions according
to the Declaration of Helsinki (WMA, 2013) and ethical approval
was obtained for both studies from the Health Research Ethics
Committee, NWU (NWU-00060-14-A1, NWU-00010-16-A1). The
study participants signed written informed consent forms
before participation. Participation was voluntarily.
Measurements
The sociodemographic and health information of the women
(age, educational status, housing, occupation, smoking,
chronic medication) were determined through an interviewer-
administered structured questionnaire. Self-reported hyperten-
sion and use of all medication were recorded. Height and
weight measurements were performed using a calibrated
digital scale with stadiometer (Seca 264, Hamburg, Germany).
Height (cm) was measured to the nearest 0.1 cm with the partici-
pant barefoot and with the head in the Frankfort plane. Weight
was measured to the nearest 0.01 kg. BMI was calculated as
weight (kg) divided by height (m) squared.34
Pregnancy tests were performed before DXA measurements to
confirm non-pregnancy. Whole-body BMD, LFN BMD and
spine BMD, fat tissue mass and fat-free tissue mass of the
whole body were measured by a registered radiographer, by
using DXA with the default Hologic settings (Hologic Discovery
W, APEX system software version 2.3.1). Percentage body fat
was calculated by the DXA software. Study participants whose
bodyweights exceeded the DXA measuring stipulations
(130 kg) could not be measured by DXA and were therefore sub-
sequently excluded from the statistical analysis. Appendicular
skeletal muscle mass (ASM) was derived as the sum of the fat-
free soft tissue mass (excluding bone) of the arms and the
legs.35 Appendicular skeletal muscle mass index was derived
from ASM (kg) divided by height (m) squared.
HIV testing
Written informed consent was obtained from each individual
participant before HIV testing. Trained HIV counsellors did
group pre-test counselling before the test. A finger prick (capil-
lary) HIV test (First Response Rapid Card Test, Premier Medical
Corporation Ltd, Kachigam, India) was performed on each par-
ticipant. In the case of a positive test result, the test was con-
firmed using the Pareeshak card test (BHAT Bio-Tech India,
Bangalore, India). The participants with positive HIV test results
received individual post-test counselling and were referred for
follow-up care and CD4 counts at their nearest healthcare
facility.
Statistical analysis
Distribution of variables was assessed using the Kolmogorov–
Smirnov test and QQ plots. Descriptive statistics (median, inter-
quartile range) was used to present the study participants’ age
and body composition variables, since all variables deviated
from the normal distribution. Categorical data were presented
as number and percentage. Differences between BMD, lean
and fat mass, trunk fat mass and ASM of HIV-positive and HIV-
negative black women was determined using the Mann–
Whitney test, while age-adjusted differences were determined
using analysis of covariance. The correlation between all vari-
ables was determined by Spearman rank correlation analysis.
Multivariable regression was done to assess associations with
BMD in the total sample and two groups separately with adjust-
ment for age, smoking, educational status, alcohol intake,
calcium intake and physical activity. HIV-positive women (n =
103) were matched with 103 HIV-negative women, paired
according to their (1) age and (2) BMI. Statistical analyses per-
formed in the total groups of HIV-positive and HIV-negative
women were repeated in the matched groups. Statistical ana-
lyses were performed using the SPSS version 25 statistical soft-
ware program (IBM Corp, Armonk, NY, USA). The level of
significance was set at p≤ 0.05.
Results
The demographic information indicated that a total of 23.1% of
the participants smoked, 78.8% lived in brick houses, 97.7% had
running water, 93.7% had flush toilets, 82.9% had electricity and
86% had televisions. In total 49.5% of the group was unem-
ployed, while 23% were wage earners such as domestic
workers or cleaners and 21.6% of the group were pensioners.
A total of 18% had no school education, 27% had a primary
school education level and 52.2% had high school education.
Accurate data regarding the HIV regimen of the women and dur-
ation of ART use could not be reported by the participants;
however, from the available data most women reported the
use of tenofovir disoproxil fumarate (TDF) 300 mg in combi-
nation with lamivudine (3TC) and efavirenz (EFV) and the dur-
ation ranged between three and eight years.
Participant characteristics for the total groups of HIV-positive
and HIV-negative women are presented in Table 1. HIV-negative
women had significantly higher median BMD, % body fat (%BF),
body mass index (BMI), waist circumference (WC), ASM and ASM
index compared with their HIV-positive counterparts. The HIV-
positive women were significantly younger than the HIV-
negative women. Smokers had significantly lower whole-body
BMD, %BF, ASM and ASM index than non-smokers. Significant
positive correlations between BMI (r = 0.51, p < 0.0001), ASM
(r = 0.09, p = 0.03), ASM index (r = 0.52, p < 0.0001), %BF (r =
0.38, p < 0.0001), respectively, and whole-body BMD were
found, as well as a negative correlation between age and
whole-body BMD (r =−0.29, p < 0.0001).
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Data were matched for HIV-negative and HIV-positive groups as
indicated in Table 2. No significant differences were found
between these two groups, but spine BMD was marginally
lower in HIV-positive women (p = 0.05) and there was also a
trend for lower LFN BMD in the same participants.
In the regression models, whole-body BMD, as well as spine BMD
and LFN BMD, respectively, were used as dependent variables.
Covariates included age, educational status, smoking, alcohol
intake, calcium intake, HIV status (total group only), as well as
physical activity level. In the total group, age, smoking and HIV
status (negative association) were associated with lower BMD,
while calcium intake and BMI were positively associated with
whole body BMD (Table 3). Smoking, BMI, dietary calcium
intake, age and HIV status explained 30.4% of the variance in
spine BMD and 38.6% of the variance in whole-body BMD.
Only age and education were found to be consistently associ-
ated with whole-body and spine BMD in the HIV-positive
group and explained 72.5% of the variance in whole-body
BMD (Table 4).
Discussion
The main finding of this study indicated that different exposures
were associated with low whole-body BMD among HIV-positive
and HIV-negative women, as well as with whole-body BMD at
the different sites. The study found that low whole-body BMD
was more common among HIV-positive women compared
with HIV-negative women. BMI, dietary calcium intake (positive)
and age (negative) were associated with whole-body BMD in
HIV-negative women. However, only age and education were
consistently associated with whole-body BMD in the HIV-posi-
tive group. This could indicate that HIV-positive women who
are older and have low education levels may be at an increased
risk for the development of low whole-body BMD.
The study found a significant positive correlation between
whole-body BMD, %BF, ASM and ASM index of HIV-positive
and HIV-negative women. No significant differences were
found between the matched groups, possibly due to the fact
that similar variables are associated with BMI and whole-body
BMD. However, spine and LFN BMD tended to be lower in HIV-
Table 1: Descriptive data for the total group (median, IQR)
Variable n HIV-negative n HIV-positive p-value*
Age (years) 439 52 (47;59) 103 47 (42;53) < 0.001
BMI (kg/m2) 439 30.5 (25;36) 103 24.7 (21;31) < 0.001
Waist circumference (cm) 439 90.3 (79;100) 103 79.1 (70;88) < 0.001
Fat percentage (%) 439 41.8 (36;46) 103 36.2 (29;41) < 0.001
Fat (kg) 439 30.7 (22;39) 103 21.4 (15;30) < 0.001
Whole-body BMD (g/cm2) 439 1.06 (0.98;1.14) 103 1.04 (0.98;1.12) 0.03
LFN BMD (g/cm2)+ 145 0.80 (0.67;0.85) 25 0.67 (0.63;0.83) 0.053
Spine BMD (g/cm2)+ 145 0.88 (0.78;0.94) 25 0.78 (0.73;0.86) 0.005
Appendicular skeletal mass (ASM) (kg) 439 17.44 (14.46;20.02) 103 15.44 (13.24;17.88) < 0.001
ASM index (kg/m2) 439 7.02 (6.04;8.07) 103 6.35 (5.50; 7.31) < 0.001
Smokers (%) 439 24.4% 103 20.4% 0.31
Alcohol (g) 439 0 (0;12.2) 103 3.4 (0;27) 0.10
Physical activity (PA) index (score) 150 2.99 (2.62;3.15) 33 2.93 (2.64;3.26) 0.12
Notes: Median and interquartile ranges (25th, 75th percentiles) are indicated for non-normally distributed data; *p-values reflect significant differences between the two
groups; Mann–Whitney test or chi-square for categorical data; +missing for some variables, LFN = left femoral neck, BMD = bone mineral density, BMI = body mass index.





n = 103 p-value*
Age (years) 48 (45;53) 48 (43;54) 0.28
Weight (kg) 61.6 (52;75) 60.8 (51;76) 0.67
Height (cm) 157.4 (152;161) 156.5 (152;160) 0.37
BMI (kg/m2) 25.1 (21;31) 24.7 (21;31) 0.85
Waist circumference (cm) 79.5 (71;93) 79.1 (71;88) 0.66
Fat percentage (%) 36.9 (32;42) 36.2 (30;42) 0.32
Body fat (kg) 22.2 (16;31) 21.4 (15;30) 0.37
BMD (g/cm2) 1.02 (0.97;1.14) 1.03 (0.95;1.09) 0.44
Spine BMD (g/cm2)* 0.88 (0.78;0.94) 0.78 (0.73;0.86) 0.05
LFN BMD (g/cm2)* 0.80 (0.67;0.85) 0.67 (0.63;0.83) 0.09
Appendicular skeletal mass (ASM) (kg) 15.56 (13.27;18.44) 15.4 (13.24; 17.84) 0.75
ASM index (kg/m2) 6.33 (5.51; 7.19) 6.35 (5.50; 7.28) 0.98
Trunk fat (kg) 10.37 (6.51;14.18) 9.21 (6.55;13.93) 0.50
Peripheral fat (kg) 12.25 (8.13;16.03) 11.32 (7.82;15.63) 0.44
Notes: Median and interquartile ranges (25th; 75th percentiles) are indicated for non-normally distributed data; p-values reflect significant differences between the two
groups, Mann–Whitney test or chi-square for categorical data; *spine and LFN BMD data were available only for 25 HIV-positive women and 45 HIV-negative women.
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positive compared with HIV-negative women. HIV infection has
been associated with low BMD in previous studies.26 Low BMD
levels were also found in young HIV-infected patients, with a
mean age of 34.6 years.36
BMI was significantly associated with whole-body BMD. A variety
of previous studies have also indicated a positive relationship
between BMI, bodyweight and BMD.37,38 An increased BMI is
thought to be protective against osteoporosis, as well as bone
loss due to the increased mechanical loading of bodyweight
on bone.39 Previous studies have also found a positive corre-
lation between body fat and BMD.37 A cross-sectional study con-
ducted by Sotunde and co-workers in a similar population group
showed lean mass had a stronger association with bone health
in comparison with fat mass.5
There are a variety of risk factors for osteoporosis, including sex,
age, race, family history, menopausal status, weight, physical
activity and smoking, as well as alcohol consumption.40–42 As
expected, age in this study was found to be associated with sig-
nificantly lower whole-body BMD at all sites.
Smoking explained some of the variance found in whole-body
BMD, but it was found to be significantly associated only with
spine BMD. Smoking is known to be a risk factor for the develop-
ment of osteoporosis, especially in the HIV-positive population
group.36 Smoking has also been linked to low BMD levels and
increased bone resorption, related to HIV infection.43,44 A posi-
tive association between alcohol intake and LFN BMD was
found in the HIV-positive group, and the direction of the associ-
ation between smoking and LFN BMDwas also positive. The HIV-
positive women in this study had generally low alcohol intakes,
with a median intake of 3.4 g/day and those who smoked used
between 2 and 10 cigarettes daily. The unexpected associations
found in this study may also be a result of the small sample size
of HIV-positive women, and should be interpreted with caution.
HIV status contributed to the variance found in whole-body BMD
in the total group. HIV infection as well as ART is known to result
in increased bone loss.26 People living with HIV have also been
found to have a 58% higher fracture rate when compared
with the general population.45–47 A variety of studies have inves-
tigated the effect of highly active antiretroviral therapy (HAART)
on BMD.48,49 This study had incomplete data regarding the HIV
regimen and duration of HAART therapy of the women;
however, most women reported the use of tenofovir disoproxil
fumarate (TDF) 300 mg in combination with lamivudine (3TC)
and efavirenz (EFV). A previously conducted study indicated
that the primary factors associated with lower baseline BMD
were low bodyweight and smoking, as well as a long period of
HIV infection (≥ 17 years).48 Antiretroviral therapy (ART) may
also affect bone metabolism through decreased activation of
calcitriol (1,25-dihydroxyvitamin D3).
50 TDF has been associated
with increased bone loss compared with other reverse transcrip-
tase inhibitors.26 Studies report that TDF usage is associated with
increased vitamin D binding protein and increased PTH, as well
as decreased free 1,25-dihydroxyvitamin D3 levels.
51 This is
indicative of a functional vitamin D deficiency with TDF usage
contributing to excess bone loss.52 A study by Dave and co-
workers (2018) on the prevalence and correlates of low BMD
in HIV-positive South Africans, found that efavirenz or lopinavir
exposure was strongly associated with a low BMD of the hip.46
The study also found that the exposure to efavirenz led to a
higher prevalence of vitamin D deficiency.46 The use of efavirenz
was also found to be inversely associated with lumbar spine
BMD, after adjustments for age, weight and sex.46
Dietary calcium intake was significantly associated with whole-
body BMD and explained some of the variance found in BMD.
Urbanisation is known to be associated with lower calcium
intake in black South African women.53 Furthermore, lower con-
sumption of milk and dairy products was found in urban than
rural women in a South African study.53 Achieving optimal
calcium levels is known to be beneficial to the attainment as
well as maintenance of BMD.54 A variety of studies have exam-
ined the effect of calcium supplementation on the risk of cardi-
ovascular events.55,56 A study conducted by Galli and co-workers
found that an optimal dietary calcium intake in HIV-infected
patients predicted a high cardiovascular risk.57 The proposed
mechanism was linked to the multifactorial causes of cardiovas-
cular risk in HIV-infected patients. This includes complex inter-
actions between traditional risk factors, lifestyle, HIV-related
and combination antiretroviral therapy factors.57
Physical activity was positively associated with LFN BMD in the
HIV-negative women. Studies conducted in high-risk population
groups such as postmenopausal women found that physical
activity improved BMD and decreased fracture risk.58,59
Limited data are available regarding the impact of physical
activity on BMD in people living with HIV, but it may produce
similar benefits.60 It appears that physical activity is particularly
associated with LFN BMD, more than spine BMD. This could be
suggestive of the hip being more involved in the movement
of large muscle groups. Strategies should therefore aim to
increase physical activity among older HIV-positive women to
prevent hip fractures. A study of strength training in 20 HIV-posi-
tive men found a significant increase in all BMD regions, specifi-
cally the femoral neck (8.45%), lumbar spine (3.28%) and 1/3
radius (5.41%).60 A similar study of brisk walking and strength
Table 3:Multiple regression models for the association with whole BMD,
spine BMD and LFN BMD in the total group (n = 542)*
Model Standardised β p-value
LFN hip BMD:
Final model, adjusted R2 = 0.396 < 0.001
Body mass index (kg/m2) 0.536 < 0.001
Dietary calcium intake (mg) 0.099 0.10
Weighted physical activity score 0.090 0.15
Age (years) −0.222 < 0.001
HIV status (HIV-negative as reference) −0.094 0.14
Spine BMD:
Final model, adjusted R2 = 0.304 < 0.001
Body mass index (kg/m2) 0.406 < 0.001
Smoking (non-smoking as the
reference)
−0.135 0.04
Dietary calcium intake (mg) 0.093 0.16
Age (years) −0.220 < 0.001
HIV status (HIV-negative as reference) −0.146 0.03
Whole-body BMD:
Final model, adjusted R2 = 0.386 < 0.001
Body mass index (kg/m2) 0.495 < 0.001
Smoking (non-smoking as the
reference)
−0.066 0.30
Dietary calcium intake (mg) 0.138 0.02
Age (years) −0.253 < 0.001
HIV status (HIV-negative as reference) −0.092 0.15
*Missing data for some variables; LFN = left femoral neck.
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positive compared with HIV-negative women. HIV infection has
been associated with low BMD in previous studies.26 Low BMD
levels were also found in young HIV-infected patients, with a
mean age of 34.6 years.36
BMI was significantly associated with whole-body BMD. A variety
of previous studies have also indicated a positive relationship
between BMI, bodyweight and BMD.37,38 An increased BMI is
thought to be protective against osteoporosis, as well as bone
loss due to the increased mechanical loading of bodyweight
on bone.39 Previous studies have also found a positive corre-
lation between body fat and BMD.37 A cross-sectional study con-
ducted by Sotunde and co-workers in a similar population group
showed lean mass had a stronger association with bone health
in comparison with fat mass.5
There are a variety of risk factors for osteoporosis, including sex,
age, race, family history, menopausal status, weight, physical
activity and smoking, as well as alcohol consumption.40–42 As
expected, age in this study was found to be associated with sig-
nificantly lower whole-body BMD at all sites.
Smoking explained some of the variance found in whole-body
BMD, but it was found to be significantly associated only with
spine BMD. Smoking is known to be a risk factor for the develop-
ment of osteoporosis, especially in the HIV-positive population
group.36 Smoking has also been linked to low BMD levels and
increased bone resorption, related to HIV infection.43,44 A posi-
tive association between alcohol intake and LFN BMD was
found in the HIV-positive group, and the direction of the associ-
ation between smoking and LFN BMDwas also positive. The HIV-
positive women in this study had generally low alcohol intakes,
with a median intake of 3.4 g/day and those who smoked used
between 2 and 10 cigarettes daily. The unexpected associations
found in this study may also be a result of the small sample size
of HIV-positive women, and should be interpreted with caution.
HIV status contributed to the variance found in whole-body BMD
in the total group. HIV infection as well as ART is known to result
in increased bone loss.26 People living with HIV have also been
found to have a 58% higher fracture rate when compared
with the general population.45–47 A variety of studies have inves-
tigated the effect of highly active antiretroviral therapy (HAART)
on BMD.48,49 This study had incomplete data regarding the HIV
regimen and duration of HAART therapy of the women;
however, most women reported the use of tenofovir disoproxil
fumarate (TDF) 300 mg in combination with lamivudine (3TC)
and efavirenz (EFV). A previously conducted study indicated
that the primary factors associated with lower baseline BMD
were low bodyweight and smoking, as well as a long period of
HIV infection (≥ 17 years).48 Antiretroviral therapy (ART) may
also affect bone metabolism through decreased activation of
calcitriol (1,25-dihydroxyvitamin D3).
50 TDF has been associated
with increased bone loss compared with other reverse transcrip-
tase inhibitors.26 Studies report that TDF usage is associated with
increased vitamin D binding protein and increased PTH, as well
as decreased free 1,25-dihydroxyvitamin D3 levels.
51 This is
indicative of a functional vitamin D deficiency with TDF usage
contributing to excess bone loss.52 A study by Dave and co-
workers (2018) on the prevalence and correlates of low BMD
in HIV-positive South Africans, found that efavirenz or lopinavir
exposure was strongly associated with a low BMD of the hip.46
The study also found that the exposure to efavirenz led to a
higher prevalence of vitamin D deficiency.46 The use of efavirenz
was also found to be inversely associated with lumbar spine
BMD, after adjustments for age, weight and sex.46
Dietary calcium intake was significantly associated with whole-
body BMD and explained some of the variance found in BMD.
Urbanisation is known to be associated with lower calcium
intake in black South African women.53 Furthermore, lower con-
sumption of milk and dairy products was found in urban than
rural women in a South African study.53 Achieving optimal
calcium levels is known to be beneficial to the attainment as
well as maintenance of BMD.54 A variety of studies have exam-
ined the effect of calcium supplementation on the risk of cardi-
ovascular events.55,56 A study conducted by Galli and co-workers
found that an optimal dietary calcium intake in HIV-infected
patients predicted a high cardiovascular risk.57 The proposed
mechanism was linked to the multifactorial causes of cardiovas-
cular risk in HIV-infected patients. This includes complex inter-
actions between traditional risk factors, lifestyle, HIV-related
and combination antiretroviral therapy factors.57
Physical activity was positively associated with LFN BMD in the
HIV-negative women. Studies conducted in high-risk population
groups such as postmenopausal women found that physical
activity improved BMD and decreased fracture risk.58,59
Limited data are available regarding the impact of physical
activity on BMD in people living with HIV, but it may produce
similar benefits.60 It appears that physical activity is particularly
associated with LFN BMD, more than spine BMD. This could be
suggestive of the hip being more involved in the movement
of large muscle groups. Strategies should therefore aim to
increase physical activity among older HIV-positive women to
prevent hip fractures. A study of strength training in 20 HIV-posi-
tive men found a significant increase in all BMD regions, specifi-
cally the femoral neck (8.45%), lumbar spine (3.28%) and 1/3
radius (5.41%).60 A similar study of brisk walking and strength
Table 3:Multiple regression models for the association with whole BMD,
spine BMD and LFN BMD in the total group (n = 542)*
Model Standardised β p-value
LFN hip BMD:
Final model, adjusted R2 = 0.396 < 0.001
Body mass index (kg/m2) 0.536 < 0.001
Dietary calcium intake (mg) 0.099 0.10
Weighted physical activity score 0.090 0.15
Age (years) −0.222 < 0.001
HIV status (HIV-negative as reference) −0.094 0.14
Spine BMD:
Final model, adjusted R2 = 0.304 < 0.001
Body mass index (kg/m2) 0.406 < 0.001
Smoking (non-smoking as the
reference)
−0.135 0.04
Dietary calcium intake (mg) 0.093 0.16
Age (years) −0.220 < 0.001
HIV status (HIV-negative as reference) −0.146 0.03
Whole-body BMD:
Final model, adjusted R2 = 0.386 < 0.001
Body mass index (kg/m2) 0.495 < 0.001
Smoking (non-smoking as the
reference)
−0.066 0.30
Dietary calcium intake (mg) 0.138 0.02
Age (years) −0.253 < 0.001
HIV status (HIV-negative as reference) −0.092 0.15
*Missing data for some variables; LFN = left femoral neck.
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training found improved spinal and femoral BMD in association
with higher physical activity.61 However, it should be noted that
both these studies had small sample sizes.62
Limitations of this study include the fact that data on dietary
intakes, alcohol intakes and physical activity, as well as site-
specific BMD were available only in a subgroup of participants.
There were therefore a smaller number of HIV-positive partici-
pants with complete data and these results should be inter-
preted with caution. However, some published studies had
similar small sample sizes.60
In conclusion we found that a decreased whole-body BMD was
more common in HIV-positive women compared with HIV-nega-
tive women. BMI and calcium intake as well as age were associ-
ated with whole-body BMD in HIV-negative women. Only age
and education were consistently associated with whole-body
BMD in HIV-positive women. In this study, physical activity was
also found to be more strongly related to LFN BMD than spine
BMD. Future intervention studies aimed at prevention of bone
loss and preservation of ASM should focus on underweight
women with low educational status, low calcium intakes, high
alcohol intakes and smokers, regardless of HIV status.
Disclosure statement – No potential conflict of interest was
reported by the authors.
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